Skip to Content

'
James C. Yao, MD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1995 Baylor College of Medicine, Houston, TX, MD
1991 Rice University, Houston, TX, BA, Computer Science

Postgraduate Training

7/1998-6/2001 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Robert A. Wolff

Board Certifications

1/2003 Board Certification in Medical Oncology (ABIM)
1/1999 Board Certification in Internal Medicine (ABIM)

Experience/Service

Administrative Appointments/Responsibilities

Deputy Department Chair, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/2007-present
Faculty Supervisor of Mid-Level Providers Program, The University of Texas MD Anderson Cancer Center Department of Gastrointestinal Medical Oncology, Houston, TX, 9/2003-present

Institutional Committee Activities

Member, Personalized Risk Prediction Program of Duncan Family Institute Steering Committee, 5/2010-present
Member, Clinical Research Program Executive Steering Committee, 12/2009-present
Member, Research and Education Information System Steering Team, 8/2009-present
Co-Chairman, Enterprise Internet Strategy Steering Team (EISST) Physician and Scientist Workgroup, 1/2008-present
Member, Southwest Oncology Group (SWOG) Executive Committee, 9/2006-present
Member, Phase II Contract (N01) Committee, 9/2006-6/2011

Honors and Awards

2011 2011 Irwin H. Krakoff Excellence in Clinical Research Award, UT MD Anderson

Professional Memberships

American Society of Clinical Oncology (ASCO)
Member, 1/2003-present
NCI Investigational Drug Steering Committee
Committee Member, 2011-present
NCI Neuroendocrine Task Force Committee
Vice Chair, 1/2008-present
North American Neuroendocrine Tumor Society (NANETS)
Vice Chair, 2009-present
North American Neuroendocrine Tumor Society (NANETS)
Executive Committee, Research Coordinator, 2007-2009
Southwest Oncology Group (SWOG)
Member, 1/2006-present
SWOG GI Committee
Investigator, 1/2007-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Kulke MH, Benson AB 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW 2nd, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. Neuroendocrine tumors. J Natl Compr Canc Netw 10(6):724-64, 6/2012. PMID: 22679117.
2. Hess GP, Chen CC, Liu Z, Yao JC, Phan AT, Hill JW. Clinical Burden of Illness in Patients With Neuroendocrine Tumors. Pancreas. e-Pub 4/2012. PMID: 22513292.
3. Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas 41(3):461-6, 4/2012. PMID: 22422138.
4. Yao JC, Phan AT. Overcoming antiangiogenic resistance. Clinical Cancer Research 17(16):5217-9, 8/2011. PMID: 21828238.
5. Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol 4(1):29, 6/2011. PMCID: PMCPMC3128039.
6. Salazar R, Reidy-Lagunes D, Yao J. Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer. Drugs 71(7):841-52, 5/2011. PMID: 21568362.
7. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29(7):934-43, 3/2011. e-Pub 1/2011. PMID: 21263089.
8. Capdevila J, Salazar R, Halperín I, Abad A, Yao JC. Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors. Cancer Metastasis Rev. Suppl 1:27-34, 3/2011. PMID: 21311955.
9. Ng CS, Charnsangavej C, Wei W, Yao JC. Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. AJR Am J Roentgenol 196(3):569-76, 3/2011. PMID: 21343498.
10. Lebwohl D, Thomas G, Lane HA, O'Reilly T, Escudier B, Yao JC, Pavel M, Franz D, Berg W, Baladi JF, Stewart J, Motzer RJ. Research and innovation in the development of everolimus for oncology. Expert Opin Drug Discov 6(3):323-38, 3/2011. PMID: 22647206.
11. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K, RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N Engl J Med 364(364(6)):514-23, 2/2011. PMID: 21306238.
12. Walsh KM, Choi M, Oberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan M, Janson ET, Cunningham JL, Vosburgh E, Sackler RS, Lifton RP, Dewan AT, Hoh J. A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocr Relat Cancer 18(1):171-80, 1/2011. PMID: 21139019.
13. Walsh KM, Choi M, Oberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan M, Janson ET, Cunningham JL, Vosburgh E, Sackler RS, Lifton RP, Dewan AT, Hoh J. A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocr Relat Cancer 18(1):171-80, 2011. e-Pub 1/2011. PMID: 21139019.
14. Yao JC, Catena L, Colao A, Paganelli G. Perspectives in the development of novel treatment approaches. Tumori 96(5):858-73, Sep-Oct, 9/2010. PMID: 21302643.
15. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, Jensen RT, North American Neuroendocrine Tumor Society (NANETS). NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39(6):735-52, 8/2010. PMID: 20664472.
16. Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, Nutting C, Bushnell DL, Caplin ME, Yao JC, North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 39(6):753-66, 8/2010. PMID: 20664473.
17. Gaur P, Leary C, Yao JC. Thymic neuroendocrine tumors: a SEER database analysis of 160 patients. Ann Surg 251(6):1117-21, 6/2010. PMID: 20485130.
18. Ajani JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, Rice DC, Yao JC, Maru DM, Hofstetter WL, Phan AT, Swisher SG. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer 116(7):1656-63, 4/2010. PMID: 20143431.
19. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O'Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao JC. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. The American Journal of Surgical Pathology 34(8):1228-30, 3/2010. PMID: 20523210.
20. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J, Phan A. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer 116(6):1446-53, 3/2010. PMID: 20108336.
21. Jia Z, Gao Y, Wang L, Li Q, Zhang J, Le X, Wei D, Yao JC, Chang DZ, Huang S, Xie K. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res 70(3):1111-9, 2/2010. e-Pub 1/2010. PMCID: PMC2840649.
22. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol 28(1):69-76, 1/2010. e-Pub 11/2009. PMID: 19933912.
23. Clark OH, Ajani JA, Benson AB 3rd, Berlin JD, Blaszkowsky LS, Byrd D, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kandeel F, Kessinger A, Kulke MH, Kunz P, Kvols L, Olson JA Jr, Ratliff TW, Salem R, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, Yao JC. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors. Jounal of the National Comprehensive Cancer Network 7(7):712, 7/2009. PMID: 19635226.
24. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC, Xie K. Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer. Clin Cancer Res 15(5):1078-0432, March 1, 1009, 2/2009. PMID: 19223493.
25. Badgwell B, Cormier JN, Xing Y, Yao JC, Bose D, Krishnan S, Pisters P, Feig B, Mansfield P. Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol 16(4):1074-1076, 1/2009. PMID: 18985270.
26. Scott LC, Yao JC, Benson AB 3rd, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TR. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Chemother Pharmacol 63(2):363-70, 12/2008. PMID: 18398613.
27. Truong CD, Li W, Feng W, Cagle P, Khoury T, Alrawi S, Xie K, Yao J, Tan D. Alpha-Methylacyl-CoA Racemase Expression is Upregulated in Gastric Adenocarcinoma: A Study of 249 Cases. Int J Clin Exp Pathol 1(6):518-523, 12/2008. PMCID: PMC480587.
28. Phan AT, Yao JC. Neuroendocrine tumors: novel approaches in the age of targeted therapy. Oncology 22(14):1617-23, 12/2008.
29. Wang L, Guan X, Zhang J, Jia Z, Wei D, Li Q, Yao J, Xie K. Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models. Int J Oncol 33(1):161-7, 12/2008. PMID: 18575762.
30. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess KR, Gupta S, Jacobs C, Mares J, Landgraf A, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. Journal of Clinical Oncology 26(26):4311-4318, 9/2008.
31. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdallas E, Fleming JB, Vauthey JN, Rashid A, Evans DB. One Hundred Years After Carcinoid: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. Journal of Clinical Oncology 26(18), 6/2008.
32. Hassan MM, Phan A, Li D, Dagohoy, CG, Leary C, Yao JC. Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiology Biomarkers Prev 17(4):959-65, 4/2008.
33. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 15(1):257-66, 3/2008.
34. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26(8):1316-23, 3/2008. e-Pub 3/2008.
35. Murthy R, Kamat P, Nunez R, Madoff DC, Gupta S, Salem R, Yao JC. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol 19(1):145-51, 1/2008.

Invited Articles
1. Metz David C, Choi Junsung, Strosberg Jonathan, Heaney Anthony P, Howden Colin W, Klimstra David, Yao James C. A rationale for multidisciplinary care in treating neuroendocrine tumours. Current Opinion 19(4):306-313, 8/2012. PMID: 22760514.
2. Dong M., Phan AT, Yao JC. New strategies for advanced neuroendocrine tumors in the era of targeted therapy. Clin Cancer Res 18(7):1830-6, 4/2012.
3. Yao JC, Hoff PM. Molecular targeted therapy for neuroendocrine tumors. Hematology/Oncology Clinics of North America 21(3):575-81, 6/2007.

Abstracts
1. Yao, JC. Effect of Everolimus Treatment on Markers of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET): Results From the Phase III RADIANT-3 Study. 2011 European Multidisciplinary Cancer Congress, 9/2011.
2. Kulke M, Siu L, Tepper J, Fisher G, Jaffe D, Haller D, Ellis L, Benedetti J, Bergsland E, Hobday T, Van Cutsen E, Pingpank J, Oberg K, Cohen S, Posner M, Yao, JC. Future Directions in the Treatments of Neuroendocrine Tumors:Consensus Report of the National Cancer Institute Neuroendocrine Clinical Trials Planning Meeting. Journal of Clinical Oncology, 1/2011.
3. Pavel M, Hainsworth JD, Baudin E, Peeters M, Hoersch D, Anthony L,Hoosen S, St. Peter J, Jehl V, Yao JC. A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial of Everolimus 1 Octreotide LAR vs. Placebo 1 Octreotide LAR in Patients with Advanced Neuroendocrine Tumors (NET) (RADIANT-2). European Society of Medical Oncology (ESMO) Congress 2011, 10/2010.
4. Yao JC, Shah MH, Ito T, Lombard-Bohas C, Wolin EM, Van Cutsem E, Sachs C, Hoosen S, Lincy J, Hobday T. A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Tumors (PNET) (RADIANT-3). European Society for Medical Oncology (ESMO) Congress 2011, 10/2010.
5. Stern L, Arora S, Willet J, Wang X, Liu Z, Yao JC. A Systematic Review of Epidemiology, Treatment Pattern, Economic and Humanistic Studies in Advanced Neuroendocrine Tumors. European Society of Medical Oncology (ESMO) Congress 2010, 10/2010.
6. Yao JC, Beaumont JL, Cella D, Choi S, Liu Z, Phan AT. Characteristics Associated with Health-Related Quality of Life of Patients with Neuroendocrine Tumor (NET). European Society of Medical Oncology (ESMO) Congress 2010, 10/2010.
7. O¨ berg K, Kulke M, Pavel M, Phan AT, Hoosen S, St. Peter J, Cherfi A, Yao JC. Prognostic and Predictive Value of Chromogranin A and Neuron-specific Enolase in Patients (PTS) with Advanced Pancreatic Neuroendocrine Tumors (PNET) Treated with Everolimus. European Society of Medical Oncology (ESMO) Congress 2010, 10/2010.
8. Mani MA, Shroff RT, Jacobs CB, Wolff RA, Ajani JA, Yao JC, Phan AT. A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma. Journal of Clinical Oncology, 2008 ASCO Annual Meeting 26, 5/2008.

Book Chapters
1. Yao JC, Xie K. Development of Novel Therapeutic Agents for Neuroendocrine Tumors. In: A Century of Advances in Neuroendocrine Tumor Biology and Treatment. Felsenstein CCCP, 370-377, 2008.
2. Yao JC, Gupta S, Vauthey JN, Evans DB. Management of Nonfunctional Islet Cell - Carcinomas of the Pancreas. In: Advanced Therapy in Surgical Oncology. Ed(s) Pollock RE, Curley SA, Ross MI, Perrier NE. BC Decker Inc. Lewiston, New York, 443-448, 2008. ISBN: 978-1-55009-126-7.
3. Yao JC, Rindi G, Evans DB. Pancreatic Endocrine Tumors. In: CANCER Principles & Practice of Oncology, 8th Edition. DeVita, 2008.

Books (edited and written)
1. Caplin M, Yao JC. Ed(s) Caplin M, Yao JC. Handbook of Gastroenteropancreatic and Thoracic NeuroendocrineTumours. Bio Scientifica: UK, 2011.
2. Yao JC, Hoff PM, Hoff AO, et al. Ed(s) Yao JC, Hoff PM, Hoff AO. Neuroendocrine Tumors. In: Current Clinical Oncology. Series Ed(s) Markman Maurie. Humana Press, 2011.

Letters to the Editor
1. Matthew H. Kulke, Emily K. Bergsland, James C. Yao. Glycemic Control in Patients with Insulinoma Treated with Everolimus. New England Journal of Medicine 360(2):195-197, 1/2009.
2. Yao JC, Kvols LK. Octreotide LAR in Carcinoid: How to Dose? Pancreas 37(3):337-338, 10/2008.

Last updated: 12/20/2012